These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 32557931)

  • 1. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
    Farnum SO; Makarenko I; Madden L; Mazhnaya A; Marcus R; Prokhorova T; Bojko MJ; Rozanova J; Dvoriak S; Islam Z; Altice FL
    Addiction; 2021 Jan; 116(1):83-93. PubMed ID: 32428276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies.
    Betts KS; Chan G; McIlwraith F; Dietze P; Whittaker E; Burns L; Alati R
    Addiction; 2016 Jul; 111(7):1214-23. PubMed ID: 26857811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
    Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
    Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Polonsky M; Marcus R; Bojko MJ; Filippovych S; Springer S; Dvoriak S; Altice FL
    Drug Alcohol Depend; 2016 Aug; 165():213-20. PubMed ID: 27370527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
    Mocanu V; Bozinoff N; Wood E; Jutras-Aswad D; Le Foll B; Lim R; Cheol Choi J; Yin Mok W; Eugenia Socias M;
    Drug Alcohol Depend; 2023 Jul; 248():109932. PubMed ID: 37224674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
    Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
    JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.
    Socías ME; Wood E; Lake S; Nolan S; Fairbairn N; Hayashi K; Shulha HP; Liu S; Kerr T; Milloy MJ
    Addiction; 2018 Dec; 113(12):2250-2258. PubMed ID: 30238568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overdose mortality rates in Croatia and factors associated with self-reported drug overdose among persons who inject drugs in three Croatian cities.
    Handanagic S; Bozicevic I; Sekerija M; Rutherford GW; Begovac J
    Int J Drug Policy; 2019 Feb; 64():95-102. PubMed ID: 30641451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid agonist treatment and risk of death or rehospitalization following injection drug use-associated bacterial and fungal infections: A cohort study in New South Wales, Australia.
    Brothers TD; Lewer D; Jones N; Colledge-Frisby S; Farrell M; Hickman M; Webster D; Hayward A; Degenhardt L
    PLoS Med; 2022 Jul; 19(7):e1004049. PubMed ID: 35853024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of emergency guidance to the COVID-19 pandemic on treatment entry, retention and mortality among patients on methadone in Ukraine.
    Ivasiy R; Madden LM; Meteliuk A; Machavariani E; Ahmad B; Zelenev A; Desai MM; Bromberg DJ; Polonsky M; Galvez de Leon SJ; Farnum SO; Islam Z; Altice FL
    Addiction; 2024 Sep; 119(9):1585-1596. PubMed ID: 38807448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis.
    Garg R; Kitchen SA; Men S; Campbell TJ; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
    Drug Alcohol Depend; 2022 Jul; 236():109459. PubMed ID: 35489179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.
    Larney S; Jones NR; Hickman M; Nielsen S; Ali R; Degenhardt L
    Addiction; 2023 Aug; 118(8):1527-1539. PubMed ID: 36843415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Marcus R; Pykalo I; Madden L; Filippovich S; Dvoriak S; Altice FL
    J Subst Abuse Treat; 2018 Apr; 87():1-8. PubMed ID: 29471921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
    Johnson B; Richert T
    Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years.
    Nordt C; Vogel M; Dey M; Moldovanyi A; Beck T; Berthel T; Walter M; Seifritz E; Dürsteler KM; Herdener M
    Addiction; 2019 Jan; 114(1):103-111. PubMed ID: 30209840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018.
    Krebs E; Homayra F; Min JE; MacDonald S; Gold L; Carter C; Nosyk B
    Drug Alcohol Depend; 2021 Aug; 225():108799. PubMed ID: 34087747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
    Sadek J; Saunders J
    BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine.
    Morozova O; Dvoriak S; Pykalo I; Altice FL
    Drug Alcohol Depend; 2017 Apr; 173():132-138. PubMed ID: 28242537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.